The guideline rests on a simple but radical premise. Malignant tumors are so complex and heterogeneous that a disease-centric model of care is no longer sufficient; instead, clinicians must adopt a patient-centric paradigm built on what the authors call cancer holistic integrative assessment, or CHIA. CHIA is characterized by four core principles: an integrative philosophy that treats the patient as a whole, multidimensional evaluation spanning clinical history to molecular biology, a dynamic and individualized process that is repeated throughout the disease course, and multidisciplinary collaboration among oncologists, psycho-oncologists, nutritionists, traditional Chinese medicine practitioners, and reproductive medicine specialists. Assessment, in this framework, is both a diagnostic procedure and a strategy to preemptively avoid treatment-induced injury.

The intellectual lineage of the guideline traces back to the mid-twentieth century, when tumor assessment focused almost exclusively on tumor size and morphology, exemplified by the 1979 WHO criteria for solid tumor response. The introduction of RECIST 1.0 in 2000 by the EORTC, U.S. NCI, and NCIC provided a simplified, reproducible measurement method, and the arrival of targeted and immune therapies later spawned newer criteria such as Choi, mRECIST, irRC, and iRECIST. In parallel, symptom-management assessment gained prominence: the Brief Pain Inventory quantified subjective pain, the Distress Thermometer enabled rapid psychological screening, and tools such as NRS-2002 and PG-SGA brought evidence-based nutritional risk assessment into routine practice. The CACA guideline weaves these threads into a single, unified pre-therapy evaluation framework.

The urgency of the effort is underscored by a nationwide survey conducted between September 2023 and February 2024 involving 2,236 healthcare professionals. The results revealed striking practice gaps: only 38.08 percent of respondents assessed performance status in every patient, psychosocial screening was offered in fewer than half of units for 61.28 percent of respondents, and genetic-risk assessment was performed in more than 10 percent of units by just 17.69 percent. While nursing assessments of pain and nutrition were robust, with coverage above 83 percent, and physician-led comorbidity assessment was common at 89.49 percent, significant barriers persisted. Roughly a third of professionals lacked knowledge or skills, 35.26 percent had no relevant training, nearly 20 percent cited absent guidelines, and almost half reported time constraints. The authors distill these obstacles into three phrases: “don’t know how,” “no time,” and “no standards.”

Technically, the guideline is remarkably granular. For general status, it mandates that evaluations of physical function, symptoms, and nutrition be completed within 24 hours of admission for inpatients. Performance status is appraised with the Karnofsky scale, scored 0 to 100 across 11 levels, and the simpler ECOG scale, scored 0 to 5, whose 1594 trial established ECOG 2 or higher as a cutoff indicating no benefit from chemotherapy in advanced non-small-cell lung cancer. For older adults, the Timed Up and Go test quantifies mobility and balance, with times under 10 seconds indicating good mobility and times over 20 seconds prompting deeper assessment. The guideline is careful to note that these scores are reference rather than absolute criteria: a breast cancer patient with a pathologic femoral fracture may still warrant surgery despite a Karnofsky score of 30, and a patient with small-cell lung cancer and ECOG 3 may still benefit from chemotherapy.

Organ function assessment occupies a central chapter. Cardiac evaluation relies on echocardiography, electrocardiography, and biomarkers such as troponin and brain natriuretic peptide, with risk-stratified monitoring schedules tied to left ventricular ejection fraction; a decline of more than 10 percent during therapy triggers treatment discontinuation and cardiopulmonary protection. Pulmonary assessment addresses the growing threat of drug-induced interstitial lung disease from chemotherapy, antibody-drug conjugates, and immunotherapy, recommending early high-resolution CT, which offers sensitivity above 90 percent, when new respiratory symptoms follow drug exposure. For thoracic surgery, the guideline integrates the Cardiopulmonary Risk Index and cardiopulmonary exercise testing, flagging high risk when FEV1 falls below 1.5 liters, DLCO below 60 percent, or VO2max below 10 mL/kg/min. Liver function is classified with the Child-Pugh system, kidney function tracked through glomerular filtration rate, and bone marrow readiness defined by thresholds such as an absolute neutrophil count of at least 1.5 × 10⁹ per liter and platelets of at least 80 × 10⁹ per liter.

Perhaps the most forward-looking sections address psychology and social context. In China, 30 to 50 percent of cancer patients experience psychological problems, and the guideline prescribes screening with the Distress Thermometer, the GAD-7 anxiety questionnaire, and depression instruments such as the PHQ-9 and HADS. Cognitive impairment receives unusual attention: 30 to 40 percent of patients show tumor-related cognitive deficits before chemotherapy, 75 percent decline during treatment, and 60 percent decline afterward, with the Mini-Mental State Examination and Montreal Cognitive Assessment serving as core tools. Sleep disorders, affecting 30 to 93.5 percent of cancer patients—roughly three times the general population—are screened with the Insomnia Severity Index and Pittsburgh Sleep Quality Index. Strikingly, the guideline also endorses novel digital tools, including a multimodal psychological system that digitizes the PHQ-9 and GAD-7 and integrates heart-rate variability monitoring; clinical data cited show that this approach raised the objective response rate to immunotherapy in advanced lung cancer from 19.3 to 34.7 percent, and virtual-reality simulation of radiotherapy environments reduced treatment-related adverse events by 41 percent.

The guideline extends assessment into domains most oncology frameworks ignore. Family and social support are quantified with validated instruments including the SCNS-SF34 needs survey, the F-COPES family coping scale, and the CSNAT caregiver tool, with family members of advanced cancer patients explicitly designated as “indirect patients” given their elevated rates of depression and anxiety. Financial toxicity is measured with the COST-PROM instrument, where scores of 22 or below indicate high financial toxicity. Tumor biology is assessed through TNM staging and molecular subtyping, drawing on landmark Chinese multi-omics work in hepatocellular carcinoma, triple-negative breast cancer, and esophageal cancer. Genetic risk chapters cover BRCA1/2-associated hereditary breast and ovarian cancer, where cumulative breast cancer risk by age 80 reaches 72 percent for BRCA1 carriers, along with Lynch syndrome, familial adenomatous polyposis, hereditary thyroid, prostate, gastric, and pancreatic cancers. Fertility protection is framed as a mandatory consideration: an early survey found that although 92 percent of young oncology patients desired children, only 20 percent retained fertility, and the guideline stratifies gonadotoxic risk by drug class and radiation dose.

Uniquely, the document closes with a traditional Chinese medicine framework, defining eight core pathogenesis patterns—qi deficiency, yang deficiency, yin deficiency, blood deficiency, qi stagnation, phlegm-dampness, blood stasis, and heat toxin—and introducing the TCM Eight-Principle Syndrome Quantitative Evaluation Tool, a 100-point instrument with basic, tongue, and pulse modules that generates radar charts for dynamic monitoring. The authors acknowledge that implementation remains the central challenge, calling for strengthened training, guideline dissemination, streamlined workflows, and digital tools. But their ambition is unmistakable: with systematic, standardized, and dynamic holistic integrative assessment, they contend, oncology can move from empirical to precision medicine, delivering care that is simultaneously safer, more effective, and more humanistic—and advancing China’s strategic “Healthy China” goal in the process.

Beyond the enumerated scales and thresholds, the guideline reflects a broader shift in how assessment itself is conceptualized. Rather than a single checkpoint before therapy begins, CHIA is framed as a continuously repeated cycle in which findings feed back into evolving treatment decisions. This dynamic quality distinguishes it from static staging systems, since a patient’s nutritional state, psychological distress, and organ reserve can change substantially between treatment lines, meaning that an assessment performed once at diagnosis may quickly become obsolete.

The document also clarifies how different assessment domains interact in practice. Comorbidity and organ-function findings determine not only whether a therapy is tolerable but which modality is preferable, while family support and financial toxicity shape whether a prescribed regimen can realistically be completed. This interdependence explains why the authors insist on multidisciplinary execution rather than assessment by a single clinician, and why nursing-led screening for pain and nutrition complements physician-led evaluation of comorbidities rather than duplicating it.

The survey findings embedded in the guideline suggest that the main obstacles to adoption are organizational rather than conceptual. Because most respondents already recognized the value of comprehensive evaluation, the authors emphasize practical remedies: embedding standardized protocols into clinical workflows, offering structured training to close knowledge gaps, and deploying digital tools that automate data collection and display results in interpretable formats. Such measures respond directly to the twin barriers of limited time and absent standards.

As integrative oncology matures, frameworks of this kind may serve as templates for other health systems seeking to operationalize patient-centered care. By consolidating validated instruments across physical, psychological, social, genetic, and traditional medicine domains into one coherent process, the guideline demonstrates that holistic assessment can be systematic and measurable rather than aspirational, offering a concrete pathway from whole-person philosophy to everyday clinical decision-making.

Subject of Research: Cancer holistic integrative assessment guidelines for patient-centered oncology evaluation

Article Title: CACA Guidelines for holistic integrative assessment (2025)

Article References: Zhang, H., Shi, Q., Li, X., Li, Q., Liu, Y., Zhang, H., Lin, R., Zhou, W., Chu, Q., Min, J., Zheng, J., Liu, B., Chen, X., He, Y., Ni, L., Li, M., Cong, M., Liang, F., Wang, X., … Liu, D. (2026). CACA Guidelines for holistic integrative assessment (2025). Holistic Integrative Oncology, 5(1), Article 70. https://doi.org/10.1007/s44178-026-00277-6

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00277-6

Keywords: CACA guidelines, holistic integrative oncology, cancer assessment, performance status, psycho-oncology, financial toxicity, genetic risk, fertility preservation, traditional Chinese medicine, precision oncology, China Anti-Cancer Association, patient-centered care

The intricate role of N6-methyladenosine (m6A), the most abundant internal modification on eukaryotic messenger RNA, has emerged as a crucial epigenetic regulator influencing tumorigenesis and cancer progression. m6A methylation modulates RNA stability, translation, and splicing, thereby orchestrating cellular processes fundamental to malignancy. STM2457, a selective inhibitor of the m6A methyltransferase METTL3, disrupts this pathway, representing an exciting therapeutic candidate for m6A-mediated cancers. However, the intrinsic limitations of monotherapy, including incomplete response and resistance, have necessitated exploring combinatorial strategies to amplify anti-tumor impact.

Astragalus polysaccharide, derived from the traditional Chinese medicinal herb Astragalus membranaceus, has been historically celebrated for its immunomodulatory and anti-inflammatory properties. Modern investigations have unveiled its antineoplastic potential, attributed to mechanisms such as macrophage activation, apoptosis induction, and inhibition of tumor angiogenesis. Wang’s study compellingly elucidates how APS can synergize with STM2457, enhancing its therapeutic efficacy in OSCC through multifaceted molecular pathways.

At the molecular interface, APS appears to facilitate a heightened response to STM2457 by modulating the tumor microenvironment and influencing key signaling cascades integral to OSCC survival and proliferation. Notably, APS treatment was shown to downregulate oncogenic pathways typically reinforced by aberrant m6A methylation, thus complementing STM2457’s mode of action. This dual modulation results in a pronounced suppression of tumor growth and metastasis, exceeding the effects observed with STM2457 monotherapy.

Delving deeper, the study employed rigorous in vitro and in vivo models to dissect the mechanistic basis of APS-driven potentiation. Cellular assays revealed that APS not only augmented the inhibition of METTL3 activity induced by STM2457 but also stabilized the expression of tumor suppressor RNAs usually destabilized through m6A modification. Furthermore, APS was observed to reprogram immune effector cells within the tumor milieu, thereby enhancing antitumor immunity and promoting apoptosis.

Importantly, the epitranscriptomic landscape within OSCC cells was profoundly altered by the combinatorial treatment. High-throughput sequencing demonstrated that the global m6A methylation profile experienced marked shifts, with critical oncogenic transcripts undergoing demethylation and subsequent degradation. This reconfiguration underscores the therapeutic potential of targeting RNA modifications to disrupt cancer-specific gene expression patterns, an area hitherto underexploited.

The implications of this study extend beyond OSCC, as m6A modifications are increasingly recognized in various malignancies, positioning APS and STM2457 as a template for integrated epigenetic interventions. By harnessing a natural product like APS to augment the efficacy of synthetic inhibitors, this research opens avenues for safer, more effective cancer therapeutics that capitalize on synergistic mechanisms instead of relying on higher drug dosages, which often bring toxic side effects.

Moreover, the findings prompt a reconsideration of traditional medicine’s role in modern oncology, highlighting how ancient compounds can be scientifically repurposed within cutting-edge molecular frameworks. APS represents a prototype for bioactive compounds that can modulate the tumor microenvironment and epigenetic regulation, potentially improving patient outcomes when combined judiciously with current targeted agents.

Clinical translation remains a critical frontier. The results mandate well-designed trials to validate the safety and efficacy of APS and STM2457 co-administration in human subjects, optimizing dosage regimens and analyzing potential biomarkers predictive of response. Pharmacokinetic and pharmacodynamic interactions must be characterized to ensure maximal therapeutic synergy with minimal adverse events.

In conclusion, Wang’s investigation into the mechanisms by which APS enhances STM2457 therapeutic outcomes delineates a novel, intricately layered approach to combating m6A-mediated oral cancer. As the oncology community grapples with the challenges of treatment resistance and tumor heterogeneity, such integrative strategies marrying traditional compounds with innovative molecular inhibitors could revolutionize cancer therapy paradigms.

This pioneering work not only deepens our understanding of m6A methylation’s role in OSCC pathogenesis but also underscores the untapped potential residing in natural polysaccharides as adjuncts to precision medicine. The intersection of epitranscriptomics and phytochemistry exemplified in this research marks a promising horizon for the development of next-generation cancer therapeutics with the potential for broad application and improved patient survival.

Subject of Research: The therapeutic mechanisms and efficacy enhancement of astragalus polysaccharide combined with STM2457 in targeting m6A RNA methylation pathways in oral squamous cell carcinoma.

Article Title: Mechanisms of astragalus polysaccharide enhancing STM2457 therapeutic efficacy in m6A-mediated OSCC treatment.

Article References:
Wang, X. Mechanisms of astragalus polysaccharide enhancing STM2457 therapeutic efficacy in m6A-mediated OSCC treatment. Med Oncol 43, 122 (2026). https://doi.org/10.1007/s12032-026-03254-1

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s12032-026-03254-1

Triple-negative breast cancer, characterized by the absence of estrogen, progesterone, and HER2 receptors, accounts for approximately 15-20% of breast cancer cases. Its aggressive nature and lack of targeted therapies make treatment particularly challenging, often relegating options to conventional chemotherapy with limited success. In this landscape, PARP inhibitors like olaparib have emerged as targeted therapies, especially effective in cancers harboring BRCA1 or BRCA2 mutations due to their role in DNA repair pathways. However, these inhibitors show limited efficacy in BRCA-proficient TNBC, necessitating novel strategies to extend their clinical utility.

The current investigation centers on Tanshinone IIA, a diterpene quinone isolated from Salvia miltiorrhiza (Danshen), known for its anti-inflammatory, antioxidant, and antineoplastic properties. Its involvement in modulating apoptosis and cell cycle regulation has piqued interest in oncology, though its combinatorial potential with existing chemotherapeutics remains underexplored. Here, the researchers probe whether Tanshinone IIA can potentiate the pro-apoptotic effects of olaparib, thereby enhancing therapeutic outcomes in TNBC cells regardless of BRCA status.

Utilizing in vitro cell culture assays, the research team treated BRCA-proficient and BRCA-deficient triple-negative breast cancer cell lines with varying concentrations of Tanshinone IIA and olaparib, both as monotherapies and in combination. Apoptosis rates, cell viability, and molecular markers associated with DNA damage and repair were meticulously quantified. The results strikingly demonstrated that combined treatment synergistically increased apoptotic cell death far beyond additive effects seen when each agent was used independently.

Mechanistically, the synergy appears to hinge upon Tanshinone IIA’s ability to exacerbate DNA damage and disrupt cellular repair pathways, thereby sensitizing cells to PARP inhibition. Particularly noteworthy was the activation of the intrinsic mitochondrial apoptosis pathway, evident from increased cytochrome c release and caspase cascade activation. Furthermore, the combination impaired homologous recombination repair efficiency, indicated by diminished RAD51 foci formation, an effect significant in both BRCA-proficient and deficient contexts.

Complementary Western blot analyses revealed that Tanshinone IIA treatment decreased expression of anti-apoptotic proteins such as Bcl-2 while upregulating pro-apoptotic Bax. This shift in the apoptotic balance, coupled with olaparib’s inhibition of PARP-mediated DNA repair, creates a metabolic and genomic environment hostile to cancer cell survival. Importantly, the combination strategy mitigated potential drug resistance mechanisms, a persistent challenge with monotherapies.

The implications of these findings are notably significant for the clinical management of TNBC. By extending the applicability of PARP inhibitors to a broader patient subset through combination with Tanshinone IIA, this approach could revolutionize current therapeutic paradigms. The dual targeting of DNA repair systems and apoptotic pathways offers a compelling rationale for subsequent preclinical animal studies and, ultimately, human clinical trials.

Notably, the study also evaluated the cytotoxicity profile of the combined treatment in non-cancerous mammary epithelial cells. Encouragingly, the synergy selectively targeted malignant cells with minimal toxicity to normal cells, suggesting potential for a favorable therapeutic index. This specificity is critical for minimizing adverse effects and improving patient quality of life during cancer treatment regimens.

The research team further explored signaling cascades modulated by the combination treatment, identifying inhibition of the NF-κB and PI3K/AKT pathways, known contributors to cancer cell survival and proliferation. Such multi-layered interference not only prompts apoptosis but also hinders metastatic potential, underscoring an additional benefit of this therapeutic approach.

While the study primarily focused on molecular and cellular responses in controlled in vitro settings, the authors emphasize the necessity of expanding into in vivo models that mimic the complex tumor microenvironment, immune interactions, and pharmacokinetic profiles. These forthcoming investigations are crucial to validate efficacy, safety, and dosing strategies that could streamline bench-to-bedside translation.

The integration of traditional natural compounds such as Tanshinone IIA with modern targeted agents exemplifies a burgeoning trend in oncology to revisit ethnopharmacology for novel drug candidates within combinatorial frameworks. The leveraging of such synergistic partnerships holds promise not only for breast cancer but also for other malignancies marked by DNA repair deficiencies and therapeutic resistance.

In summary, this study delineates a compelling new avenue in the fight against triple-negative breast cancer, demonstrating that Tanshinone IIA robustly enhances the apoptotic effect of the PARP inhibitor olaparib in both BRCA-proficient and -deficient TNBC cells. The mechanistic insights into DNA damage accumulation, repair inhibition, and apoptosis induction furnish valuable directions for future clinical development. As oncologists grapple with the heterogeneity and aggressiveness of TNBC, such innovative combination therapies could shift treatment paradigms and improve prognoses for many patients worldwide.

With ongoing advances, the therapeutic landscape of breast cancer is evolving rapidly, with research such as this exemplifying how natural compounds can be harnessed to amplify the efficacy of existing drugs. The dual assault on cancer cell DNA integrity and survival signaling presents a multidimensional strategy that may overcome the limitations of monotherapy. If validated in clinical settings, Tanshinone IIA and olaparib co-therapy can become a vital option in personalized cancer care.

As the scientific community continues to dissect the intricate mechanisms behind TNBC and its resistance strategies, integrative approaches combining molecular targeted agents and phytochemicals are poised to redefine the future of oncologic therapeutics. This study illuminates one such promising path, offering renewed optimism against a formidable disease.

Subject of Research: The synergistic anticancer effects of Tanshinone IIA combined with the PARP inhibitor olaparib in treating BRCA-proficient and -deficient triple-negative breast cancer cells.

Article Title: Tanshinone IIA is synergistic with the PARP inhibitor olaparib in inducing BRCAs-proficient and -deficient triple-negative breast cancer cell apoptosis.

Article References: Liu, Q., Zhou, Q., Yang, X. et al. Tanshinone IIA is synergistic with the PARP inhibitor olaparib in inducing BRCAs-proficient and -deficient triple-negative breast cancer cell apoptosis. Med Oncol 42, 419 (2025). https://doi.org/10.1007/s12032-025-02968-y

Image Credits: AI Generated